GLPG vs. BPMC, VKTX, IONS, CYTK, SMMT, OGN, MDGL, NUVL, BBIO, and APLS
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), Organon & Co. (OGN), Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines (NASDAQ:BPMC) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
32.5% of Galapagos shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Blueprint Medicines presently has a consensus target price of $108.00, indicating a potential upside of 4.51%. Galapagos has a consensus target price of $34.50, indicating a potential upside of 28.92%. Given Blueprint Medicines' higher possible upside, analysts clearly believe Galapagos is more favorable than Blueprint Medicines.
Blueprint Medicines received 54 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 67.89% of users gave Blueprint Medicines an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Galapagos has higher revenue and earnings than Blueprint Medicines.
Galapagos has a net margin of -26.25% compared to Galapagos' net margin of -102.15%. Blueprint Medicines' return on equity of -2.60% beat Galapagos' return on equity.
In the previous week, Blueprint Medicines had 11 more articles in the media than Galapagos. MarketBeat recorded 14 mentions for Blueprint Medicines and 3 mentions for Galapagos. Galapagos' average media sentiment score of 0.43 beat Blueprint Medicines' score of 0.07 indicating that Blueprint Medicines is being referred to more favorably in the media.
Blueprint Medicines has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Summary
Blueprint Medicines beats Galapagos on 10 of the 17 factors compared between the two stocks.
Ad DTI
Most people would never touch this orange powder… would you?
At first glance, it looks like some ordinary “orange” powder…
But in reality, it is a scientific breakthrough in energy technology.
One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years.
And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out.
The question is…
Why are the top 1% piling in this much?
And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?
Well, all the answers you need are right here
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
